Eliem Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019
Selling, General & Admin	24.86	18.92	12.35	2.43	0.68
Research & Development	15.41	26.21	23.32	9.34	4.02
Other Operating Expenses	0	0	0	9.16	2.75
Operating Expenses	40.28	45.14	35.67	20.93	7.45
Operating Income	-40.28	-45.14	-35.67	-20.93	-7.45
Other Expense / Income	-5.16	0.11	11.81	-0.26	-0.9
Pretax Income	-35.12	-45.24	-47.48	-20.67	-6.55
Net Income	-35.12	-45.24	-47.48	-20.67	-6.55
Preferred Dividends	0	0	4.55	2.29	0.84
Net Income Common	-35.12	-45.24	-52.03	-22.95	-7.39
Shares Outstanding (Basic)	27	26	12	2	2
Shares Outstanding (Diluted)	27	26	12	2	2
Shares Change	2.57%	114.60%	460.40%	31.72%	-
EPS (Basic)	-1.30	-1.72	-4.24	-10.49	-4.45
EPS (Diluted)	-1.30	-1.72	-4.24	-10.49	-4.45
Free Cash Flow	-20.6	-37.37	-36.07	-14.1	-5.01
Free Cash Flow Per Share	-0.76	-1.42	-2.94	-6.44	-3.02
EBITDA	-34.71	-44.8	-47.48	-20.67	-6.55
Depreciation & Amortization	0.41	0.44	0	0	0
EBIT	-35.12	-45.24	-47.48	-20.67	-6.55

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).